sma survey result line
model
confer call today et dial
survey us neurologist treat sma patient uptak
buy spinraza intrathec novarti novn-swx nr zolgensma
gene therapi ahead buy risdiplam oral data present
survey result line model view spinraza competitor
eros risdiplam uptak longer term
host
initi buy pt pipelin deep dive
initi buy pt deep-div
correct issu correct properli state model
spinraza sale prior note state spinraza sale
survey neurologist treat sma patient na sma
preval popul survey result in-lin model
spinraza eros time anticip increas uptak zolgensma
one-tim gene therapi risdiplam liquid oral
current model peak spinraza sale erod
street estim
assum increas uptak zolgensma risdiplam pend approv
assum greater sale eros
stock could neg impact spinraza sale erod
y/i start fv stock could neg impact
sh spinraza goe away complet fv stock could
neg impact
near-term believ spinraza maintain share type pediatr
adult sma patient zolgensma like take share us
infant newli diagnos sma patient survey result show
respond believ zolgensma effect type patient
compar respond chose spinraza
risdiplam caveat risdiplam approv yet given
posit top-line data survey result reflect risdiplam data ahead approv
launch uptak may chang time
appli survey assumpt dcf goe appli survey
assumpt see sale peak sale vs
strh sale peak
model unadjust risdiplam global sale note street
see street lack confid commerci execut risdiplam base survey believ
increas uptak type switch spinraza long-term
expect potenti filing/approv risdiplam us file eu
page
page
buy lot debat long-onli fund stock main thing
aducanumab data alzheim diseas ad key ad sever key catalyst
concern investor expos stock could run investor may
under-perform investor sever opportun get follow catalyst ad data
ctad dec fda file fda accept adcomm potenti approv
tecfidera ipr feb anoth key overhang stock recent sawai
nr settlement could see settlement await
result feb
investor awar either event go south investor expos could lose big
skeptic around qualiti ad data approv broad label remain uncertain
safety/dur data expect ctad decemb model peak adjust sale ad
note could volatil around stock even lose tecfidera ipr focu
remain ad believ easi stock given catalyst
page
buy investor skeptic manag concern
drug market investor dont think theyr effect time
better drug patient
view care look model could help investor understand leverag model
take investor may like drug drug avail platform stori
unusu much leverag model think hold back
day
page
conduct survey ahead risdiplam data present confer
biogen spinraza face competit near-term conduct survey gaug physician
prescrib trend uptak approv therapi spinraza zolgensma risdiplam
report posit top-line data await clariti qualiti data
present confer
expect potenti filing/approv us file eu
survey methodolog survey pediatr gener neurologist us cumul
treat sma patient type make total sma patient care
accord preval sma us/canada thu survey neurologist
treat roughli total north america sma preval popul
sma spinal muscular atrophi rare genet neuromuscular diseas character progress
muscl atrophi loss motor function caus lack function smn protein
incid estim live birth
sma type character sever diseas type fatal
page
neurologist survey believ spinraza potent drug sma patient base
experi data said zolgensma potent correct underli
gene believ risdiplam potent base mechan action
common patient complaint respond spinraza includ intrathec procedur
toler access/reimburs
could see shift toward zolgensma risdiplam respond want see data
survey suggest year follow-up data would make respond comfort prescrib
zolgensma risdiplam
accord survey respond said would switch type patient
spinraza risdiplam year approv year approv respond said
would switch type patient risdiplam
respond said would like definit like prescrib zolgensma first
spinraza approv children
respond believ weight-bas liquid administr risdiplam infant
issu risdiplam approv respond would equal like prescrib risdiplam
spinraza patient suggest respond need see data
page
survey suggest competit eros spinraza in-lin model
assum greater sale eros stock could
neg impact spinraza sale erod y/i start fv stock
could neg impact spinraza goe away complet fv
stock could neg impact
current model peak spinraza sale erod
street estim assum increas uptak zolgensma
risdiplam pend approv
near-term believ spinraza maintain share type sma patient children
adult zolgensma like take share us infant newli diagnos sma
patient survey result show respond believ zolgensma effect
type patient compar respond chose spinraza
anticip risdiplam fda file potenti approval/launch
pushback respond lack long-term data uptak may take time
long-term base survey could see greater uptak zolgensma risdiplam among
take despit sma competit potenti spinraza sale eros spinraza key part
valuat believ biib valuat focus ad approv tecfidera ipr
page
survey takeaway
base survey could see sale eros biib spinraza next year zolgensma
potenti risdiplam pend approv like take share
also note biib spinraza first mover advantag spinraza approv
reimburs global thu take time zolgensma expand global reach improv
access/reimburs payer limit access zolgensma approv use infant
month label say
respond said spinraza use increas next year compar zolgensma
risdiplam indic respond time like use zolgensma risdiplam
spinraza util may decreas time
survey result suggest cur gene therapi approach zolgensma infant
conveni dose risdiplam oral formul attract reason start therapi
switch spinraza
spinraza approv countri improv access took time implement
reimburs take time us rest world row countri countri basi
page
model eros beyond account competit
spinraza transit patient mainten dose see lumpi quarterli
page
survey result in-lin launch ramp assumpt model
caveat risdiplam approv yet given posit top-line data survey
result reflect risdiplam data ahead approv launch uptak may chang time
appli survey assumpt dcf goe appli survey assumpt see
sale peak sale vs strh sale peak
note street risdiplam sale compar
unadjust global sale see street lack confid commerci
execut risdiplam believ base survey result increas uptak
type switch spinraza long-term
appli survey result assum post launch risdiplam penetr type
type type appli growth post-launch penetr rate
type type type see royalti compar
current model sale
current model penetr type type type us
sale ex-u sale model aggress street
risdiplam launch assum royalti
page
survey takeaway
survey result suggest time risdiplam could increas uptak children adult
sma type physician survey need see safeti data suggest
safeti data would make comfort prescrib risdiplam
rank order efficaci sma patient respond chose spinraza chose zolgensma
respond select risdiplam
given lack long-term data survey result regard percept risdiplam could improv
time need wait see qualiti data well physician uptak
follow potenti approv data hold
survey result suggest fatigu could pushback patient spinraza
conveni dose risdiplam could attract prefer administr
spinraza thu physician like switch patient spinraza risdiplam time
survey show approv physician like switch type patient
spinraza risdiplam year patient like switch year
respond survey cite spinraza difficult administ inconveni
risidplam would equal prescrib spinraza approv given conveni dose
page
spinraza approv countri patient spinraza global
await approv countri zolgensma note patient
therapi global septemb approv countri formal
reimburs countri
us adult sma patient treat spinraza grew q/q report
adult sma patient us treat spinraza
page
believ spinraza still preferenti competitor
spinraza year data physician patient familiar
data administr safety/efficaci profil accord doc check
spinraza two competitor novarti novn-swx nr zolgensma approv may us
ptc/roch rog sw nr risdiplam could meaning impact
includ key pushback kol check
zolgensma appeal given once-onli iv administr gene therapi howev
patient concern long-term safety/dur infant develop liver
pushback use zolgensma includ
access/cost zolgensma treatment cost insur limit age
administr label less
dilut effect grow tissu
risdiplam oral formul offer conveni dose schedul life-long mainten
regimen mechan action spinraza
lack long-term data keep physicians/pati wait data encourag
page
spinraza differenti broad label includ peds/adult across sma type
addit differenti label spinraza larger number patient treat spinraza
longer durat treatment safeti data compar competitor
approv spinraza pt data durat follow-up wherea zolgensma
follow-up data
page
drug label descriptionspinrazazolgensmaapprov datedecemb indic usagebroad label indic treatment sma pediatr adult onsetal sma includ pre-symptomat rout administrationintrathec administr min first dose everi everi monthsone-hr iv infus op administrationpost-treatmentcontinu steroid least month assess liver function weekli month everi week monthswhen result clinical/lab test liver function clean begin steroid taper next day assess platelet troponin-i inject year per maintainenac year instal plan per txblack boxnaacut seriou liver injuri elev aminotransferas biotech
think sma franchis may see headwind incom competit
spinraza intrathec administr could limit penetr older children adult
heard kol spinraza oligonucleotid charg larg
make difficult diffus block drainag system fluid brain need
maintain equilibrium fluid need remov displac spinraza
gene therapi use aav eleg solut get brain immune-protect
neuron dont get gene therapi die
page
splice splice gene replacementdrug typeasosmal moleculegen therapydrug load dose mainten dose everi monthsonc dailyon timebodi distributioncn onlysystemicsystemictarget populationapprov typesal typesapprov children annual smn biotech
spinraza administr conveni could impact growth
competitor dose appeal oral regimen one-tim gene therapi administr
page
drugspinrazarisdiplamzolgensmacom intrathec fatigu requir intrathec administr facil cost good safeti far enough efficaci safeti data liquid oral formul weight-bas could dififcult administ home liver tox dilut effect reimburs narrow patient popul
despit near-term approv could take time competit erod spinraza share
expect data experi zolgensma risdiplam take share
spinraza begin beyond
zolgensma approv sma children sever insur compani
reimburs infant month
page
commentdrug classdrugtarget patient ema ema j-nda j-nda filingsmal molecul oral sma type type type therapi iv risdiplamdrug classdrugtarget patient populationphas type part primari efficaci analysessmal molecul oral risdiplamsma type part primari efficaci analysessma type initi datamyostatin inhibitor iv type pk/pd dataphas updat long-term datagen therapi iv zolgensmaphas updat datapre-sym sma type updat datagen therapi intrathec zolgensmasma type updat datapoc studi sma top-line poc studysmal molecul oral firdapsesma type interim month top-line month datasmal molecul oral branaplam type initl datasma type sunfish sma type firefish sma type
spinraza approv sma type age group
page
sma typesma type type type type sever common formsymptom onset monthssymptom onset onsetag symptom onset monthsabl sit/stand walkabl walk difficulti never abl sitmuscl weakness/skelet deformitiesmuscl weakness/skelet deform shor tlife expectancyshorten life expectancyclos normal life expect genesmost genesmost gene walk test hine motor milestoneshand held dynamometry/mmthammersmith expand cmapforc vital capacityhand held dynamometry/mmt biomarkerscmapforc vital capac biomark cmap biomark outcom measuresphenotyp
similar efficaci across drug type see eros
howev type smallest share
view type children adult preval higher major opportun
page
spinrazarisdiplamzolgensmaendear studi post treatmentinf dose select confirmatori part zolgensma trial use sit second risdiplam least five second
page
next year spinraza use may erod increas uptak zolgensma risdiplam
page
survey pediatr gener neurologist us
follow best describ
follow best describ practic
page
respond moder extrem familiar emerg therapi sma
respond involv clinic trial survey
page
strh research gener neurologist pediatr neurologist
page
pediatr neurologist treat sma pt gener neurologist treat sma pt
page
sma patient care type reflect natur histori preval
strh research gener neurologist pediatr neurologist
page
respond experi use zolgensma
page
sma type sma type patient spinraza
percentag patient follow type
sma current spinraza
page
among gener neurologist half sma type patient spinraza
gener neurologist percentag
patient follow type sma current
page
pediatr neurologist mostli see sma type patient spinraza
pediatr neurologist percentag patient
follow type sma current spinraza
page
access/reimburs key pushback spinraza treatment
sma patient current spinraza
lack insurance/
well/ lack
page
accord respond spinraza in-lin expect efficaci
page
spinraza discontinu rate low
page
sma patient discontinu spinraza due se/advanc diseas lack perceiv benefit
page
rout deliveri common complaint
page
sma patient elig spinraza take treatment despit intrathec administr
page
zolgensma rank lead contend far term efficaci type patient
page
type patient zolgensma spinraza perceiv effect
page
type respond believ spinraza effect
page
respond prescrib zolgensma type pre-symptomat infant
page
respond expect see greater prescrib zolgensma next month
page
current market split spinraza zolgensma potent drug
page
respond believ spinraza potent given experi
base person
experi
solid spinraza
well know
sure
experi w/
spinraza think
effect
shown efficaci improv muscl
clinic data direct
experi especi
otherwis healthi patient
well experi
far
pleas efficaci
page
respond believ zolgensma potent correct underli gene
base patient
medic efficaci
seem slightli superior
base upon slow disabl
progress improv
qualiti life
slightli superior
zolgensma
potent sma
base patient
medic efficaci seem
disabl progress improv
qualiti life
one time done gene replac
therapi best treatment
zolgensma correct underli
page
respond /definit like prescrib zolgensma approv
definit like
prescrib zolgensma
page
respond find risdiplam data type encourag wait use new patient
pivot firefish risdiplam data type data
hold next month would prescrib
risdiplam infant drug approv
promis inde
would good
option
treatment sma
much easier dose
compar spinraza
wait year
oral product
attract
new patient switch
spinraza receiv
clinic data look
promis need final
data fda approv
page
howev respond want safeti data attent liver tox
close monitor
reduc risk
probabl see larger
sampl seem revers
sma wors liver issu
easili monitor
wait year
ye need long-
term data safeti
particularli regard
concern dont
long term data product
patient popul
page
approv respond would equal prescrib risdiplam spinraza
page
approv respond would consid prescrib risdiplam type patient
page
respond would prescrib risdiplam newli diagnos type
page
switch spinraza risdiplam take time
page
type administr dose schedul reimburs major pushback
page
risdiplam oral liquid administr conveni easi administ
pediatr use use
product dose base weight
wait year
see
major limit
risdiplam compar
intrathec inject
issu still
conveni deliveri
med
pediatr world
page
oral dose like preferenti type patient
compar administr weight-bas dose issu type patient
page
averag respond want follow-up data get comfort risdiplam zolgensma
page
respond want see safeti data gain confid zolgensma
respond want see least data respond want see
data order feel comfort prescrib zolgensma
page
impact diseas progress type patient motor improv concern
type patient would strong efficaci data need order compel
enough use zolgensma type patient
signific impact diseas progress
even moder advanc case
efficaci older teenag
adult patient
mainten motor
function improv
one year
like metric
revers disabl
halt disabl
attain motor
mileston otherwis
expect good
sustain benefit
improv
would need fda
see data show
impact mobil skill
page
risdiplam data still compel enough prove efficaci despit shorter durat therapi
long enough trial
enough patient enrol
firefish studi
small make
confid statist
promis find
appear effect
somewhat better
conveni
respons rate
definit suffici
page
respond want see ventil swallow abil primari outcom measur
like inform
compon
primari
strength respiratori
muscl import
key
qualiti life
ye repres
import
metric consid
page
assist feed tube common sma
page
breathing/respiratori support concern sma type patient
page
page
valuat risk
target price deriv dcf assum ms sale declin
spinraza peak sale adjust ad sale model
dcf termin growth rate discount rate instead matur
biotech compani account potenti commerci execut ad termin valu
arriv tp
risk includ on-going fda reject aducanumab bla file ad competit sma
valuat risk
pt deriv use probability-adjust dcf use discount rate believ
appropri risk associ smid-cap biotech compani use termin valu
given pipelin potenti project probability-adjust peak sale
tegsedi waylivra risdiplam aadc risk stock includ inabl
commerci build commerci team gene therapi platform inabl compet sma
market receiv regulatori approv market product neg read-through
lead splice program deeper pipelin
valuat risk
pt deriv probabl adjust dcf use discount rate line
larg cap biotech compani assign termin growth rate account pipelin
assign valu pipelin upsid risk includ dupix beat expect compani
provid greater clariti oncolog strategi downsid risk includ eylea biosimilar enter
market earlier expect dupix uptak poorer anticip better data competit
versu dupix clariti implement price
compani mention note
robyn karnauska herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
